Advances in Antithrombotic Therapy: Novel Agents
Advances in Antithrombotic Therapy: Novel Agents
复制标题
抗血栓治疗的进展：新药
作者：
A. Turpie;J. Weitz;J. Hirsh
Most of the clinical evaluation of the direct thrombin inhibitors has been in coronary artery disease. The recent clinical reports suggest that there is a narrower window of safety with recombinant hirudin than initially thought particularly when it is used in conjunction with thrombolytic agents and aspirin in acute myocardial infarction. The efficacy data, however, indicate that the direct thrombin inhibitors have great potential particularly in the initial management of patients with acute unstable angina and non-Q-wave infarction. There is much to learn regarding the mechanism of action, optimal dose, and optimal concomitant therapy in the use of direct thrombin inhibitors in the management of acute coronary ischaemia; and since hirudin and other direct thrombin inhibitors have so much potential in the management of acute coronary ischaemia, it is critical that dose-finding studies be performed to determine safe regimens of these agents to allow their evaluation in large-scale trials with important clinical outcomes. The direct thrombin inhibitors have also shown to have promise in the prevention of deep vein thrombosis in high-risk surgical patients. There is limited clinical data on the other novel anticoagulants which are currently being developed.
登录
查看更多内容
抑制因子 VIIa/组织因子诱导的凝血：特别强调因子 Xa 依赖性抑制机制。
影响因子：
20.3
作者：
Rapaport,SI
通讯作者：
Rapaport,SI
狒狒血管内支架形成抗肝素血栓。
影响因子：
37.8
作者：
Krpski,WC;Bass,A;Kelly,AB;Marzec,UM;Hanson,SR;Harker,LA
通讯作者：
Harker,LA
影响因子：
56.9
作者：
RYDEL, TJ;RAVICHANDRAN, KG;FENTON, JW
通讯作者：
FENTON, JW
在灵长类动物模型中人活化蛋白 C 抑制血小板依赖性血栓形成。
影响因子：
20.3
作者：
Gruber,A;Griffin,JH;Harker,LA;Hanson,SR
通讯作者：
Hanson,SR
DOI：
10.1073/pnas.86.8.2839
发表时间：
1989-04-01
影响因子：
11.1
作者：
WILCOX, JN;SMITH, KM;GORDON, D
通讯作者：
GORDON, D